✦ LIBER ✦

Treatment of chronic non-A, non-B hepatitis with acyclovir: Pilot study

✍ Scribed by S. Chris Pappas; Dr. Jay H. Hoofnagle; Neal Young; Stephen E. Straus; E. Anthony Jones

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 576 KB
Volume: 15
Category: Article
ISSN: 0146-6615
DOI: 10.1002/jmv.1890150102

No coin nor oath required. For personal study only.

✦ Synopsis

Five patients with chronic non-A, non-B hepatitis were entered into a pilot therapeutic study of the antiviral agent acyclovir [9-(2-hydroxyethoxymethyl) guanine]. Each patient received acyclovir by slow intravenous infusion in a dosage of 5 mg/kg every 8 hr for 10 days. During therapy, serum aminotransferase levels decreased by more than 50% in two patients, remained unchanged in two patients, and rose (by 32%) in the final patient. The two patients whose serum aminotransferase levels decreased during acyclovir treatment subsequently received a second course of drug using a higher dose (10 mg/kg every 8 hr for 10 days). Serum aminotransferase levels rose in both patients (by 54% and 121%) during the second course of therapy. Acyclovir was well tolerated in these patients, and there were no symptoms or signs attributable to drug toxicity during or after treatment. During a subsequent 12-month follow-up period, none of the five patients has manifested either a clinical or serum biochemical improvement in their chronic liver disease. Spontaneous fluctuations in serum aminotransferase levels unrelated to acyclovir therapy were noted in three of the five patients. These findings suggest that a short course of acyclovir does not have any appreciable long-term beneficial effect on the course of chronic non-A, non-B hepatitis.

📜 SIMILAR VOLUMES

Non-A, non-b hepatitis in chimpanzees: I

Non-A, non-b hepatitis in chimpanzees: Interference with acute hepatitis A virus and chronic hepatitis B virus infections

✍ Dr. Daniel W. Bradley; James E. Maynard; Karen A. McCaustland; Bert L. Murphy; E 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 2 views

Two chimpanzees with persistent non-A, non-B (NANB) hepatitis were superinfected with marmoset-passaged MS-1 HAV. Two control chimpanzees were also infected with marmoset-passaged HAV. Neither animal with persistent NANB hepatitis developed elevated alanine aminotransferase (ALT) activity, whereas b

A pilot study of 2′,3′-dideoxyinosine fo

A pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis B

✍ Michael W. Fried; Julia C. Korenman; Adrian M. Di Bisceglie; Yoon Park; Jeanne G 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 1 views

The nucleoside analog 2',3'-dideoxyinosine, currently being used to treat patients infected with the human immunodeficiency virus, has been shown to inhibit viral replication in certain cell culture systems of hepatitis B virus and the duck model of chronic hepatitis B infection. We studied the effe

Thymosin treatment of chronic hepatitis

Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial

✍ Milton G. Mutchnick; Henry D. Appelman; H. T. Chung; Emma Aragona; Tej P. Gupta; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 828 KB

Chronic hepatitis B is a severe and frequently progressive disease. We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liv

Treatment of children with chronic hepat

Treatment of children with chronic hepatitis C with recombinant interferon-α: A pilot study

✍ Mercedes Ruiz-Moreno; Maria José Rua; Inmaculada Castillo; Maria Dolores García- 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Twelve children with chronic non-A, non-B hepatitis were entered in a pilot trial of recombinant interferon-alpha. Although all the children had hepatitis C virus RNA in serum, only five had antibodies against this virus. Children received 3 MU/m2 body surface area interferon-alpha 3 times/wk for 6

Hepatitis C viraemia rebound after “succ

Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non-A, non-B hepatitis

✍ Dr. J. A. Garson; S. Brillanti; C. Ring; P. Perini; M. Miglioli; L. Barbara 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 1 views

## Abstract A quantitative polymerase chain reaction (PCR) assay for hepatitis C viral RNA (HCV‐RNA) was used to monitor viraemia levels in six patients at multiple time points before, during, and after interferon therapy for chronic non‐A, non‐B hepatitis (NANBH). Prior to therapy, serum HCV‐RNA w

Non-A, non-B chronic hepatitis is chroni

Non-A, non-B chronic hepatitis is chronic hepatitis C: A sensitive assay for detection of hepatitis C virus RNA in the liver

✍ Kazuhiko Hosoda; Masao Omata; Osamu Yokosuka; Naoya Kato; Masao Ohto 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB

To study the role of hepatitis C virus in non-A, non-B chronic hepatitis, 49 liver biopsy samples from 40 patients with non-A, non-B chronic hepatitis and 9 control patients were analyzed by complementary DNA/polymerase chain reaction. Two segments of the HCV genome, one in the nonstructural region